Aldeyra Therapeutics said that a phase 2 trial of its retinitis pigmentosa candidate ADX-2191 showed the therapy led to significant results.
https://seekingalpha.com/news/3986325-aldeyra-reports-positive-mid-stage-results-retinitis-pigmentosa-candidate
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.